Previous 10 | Next 10 |
2023-08-07 12:46:32 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$1.13 and the consensus Revenue Estimate is $3.5M (-44.3% Y/Y). Over the last 2 years, ...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its seco...
2023-07-21 17:17:13 ET Gainers: Gritstone bio ( GRTS ) +4.8% . LexinFintech Holdings ( LX ) +4.3% . AppLovin ( APP ) +2.9% . Latham Group ( SWIM ) +2.6% . Accuray ( ARAY ) +2.5% . Losers: ALX Oncology Holdings ( ALXO ...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 ...
-- New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations -- -- Consistent with prior guidance, exploring partnership opportunities to advance development...
2023-05-10 22:12:05 ET Syros Pharmaceuticals, Inc. (SYRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:30 ET Company Participants Karen Hunady - Director, Investor Relations and Corporate Communications Nancy Simonian - President, CEO & Director David Ro...
2023-05-10 07:32:55 ET Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q1 GAAP EPS of -$0.85 beats by $0.20 . Revenue of $3M (-45.2% Y/Y) misses by $0.3M . Cash, cash equivalents and marketable securities as of March 31, 2023 were $166 million, as compa...
-- On track to complete enrollment of 190 patients in 4Q 2023, with pivotal complete response (CR) data from SELECT-MDS-1 expected in 3Q 2024 -- -- Amended SELECT-MDS-1 study to add overall survival as key secondary endpoint -- -- Initial data from the randomized portion o...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities ...
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its firs...
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
2024-07-17 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...